In view of possible equivalent efficacy of low dose abiraterone with food, has anyone had clinical experience offering low dose abiraterone to spare patients from financial toxicity of abiraterone?

The Szmulewitz study is a well done and robust pharmacokinetic study of low dose abiraterone with food. There is a well written commentary from Glenn Liu in the same issue of JCO.

While the study does show pharmacokinetic equivalence, it is difficult to extrapolate comfortably to clinical equivalence...